Genome-Wide MicroRNA Expression in Small Intestine Neuroendocrine Tumors (“Midgut carcinoids”): Upregulation of miRNA-182, miRNA-183 and Downregulation of miRNA-215 Abstract #200

Introduction: MicroRNAs (miRs) may regulate cell proliferation, differentiation, apoptosis and function as tumor suppressors or oncogenes. MiR expression is not characterized in neuroendocrine midgut carcinoids.
Aim(s): Investigate miR expression of normal dissected enterochromaffin cells and tumor material to find potential involvement in tumor progression.
Materials and methods: MiR expression in patient material (five primary tumors; five mesentery and five liver metastases) and in laser-microdissected normal enterochromaffin cells and three normal ilea mucosa specimens was analyzed using miRNA Affymetrix microarray. Results were validated both with Q-RT-PCR and Northern Blot.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: PhD student Su-Chen Li

To read results and conclusion, please login ...

Further abstracts you may be interested in

#355 MicroRNA Signatures as Novel Biomarkers in Small Intestine Neuroendocrine Tumors
Introduction: Small intestine (SI) neuroendocrine tumors (NET) arise from serotonin-producing intraepithelial cells in the SI referred to as enterochromafin cells. The detection of SI-NETs is often concomitant with the appearance of hepatic metastasis thus most patients with SI-NET have metastases at initial presentation. MicroRNAs (miRs) are post-transcriptional key regulators in tumorigenesis which regulate expression of other genes. Little evidence of miR expression or deregulation in SI-NETs has been reported.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Ahmed E, Martijn C, Lloyd R, ...
#422 The Somatostatin Analogue Octreotide Inhibits Growth of Neuroendocrine Tumor Cells by Triggering Janus Faced Proteins
Introduction: Octreotide is a somatostatin analogue, which improves the management of neuroendocrine tumor (NET) patients. Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful therapy or curative effects are largely unknown, particularly when SSTRs levels are low or absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Cui T, Essaghir A, ...
#424 Role of MicroRNAs in Small Intestine Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) arise from enterochromaffin cells, which belong to the endocrine system. MicroRNAs (miRs) are post-transcriptional regulators. They control multiple biological processes often functioning either as tumor suppressor genes or oncogenes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...
#585 Global microRNA profiling of small intestine neuroendocrine tumors (SI-NETs) and establishment of a method to study serum microRNA expression from the same tumors
Introduction: MicroRNAs (miRNAs) are important post-transcriptional regulatorsin biological processes and function either as tumor suppressors or oncogenes.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...